Mobia Medical, Inc. Common Stock

Mobia Medical initiated full-year 2026 revenue guidance of $54 million to $56 million, representing 69% to 75% growth over the prior year. The company reported second-quarter revenue of $13.5 million, a 102% increase year-over-year, with a gross margin of 83.2%. Selling, general and administrative expenses were $26.9 million, and the net loss was $21.0 million, or $1.10 per share. Cash and cash equivalents stood at $177.1 million as of June 30, 2026, following the May initial public offering that raised $134 million in net proceeds. Management expects gross margin to remain in the low 80s and highlighted reimbursement stability through a Category 1 CPT code and New Tech APC 1580 with Medicare reimbursement of approximately $45,000.

Mobia Medical has appointed Myriam Curet, M.D., to its board as an independent director effective July 30, 2026. Dr. Curet is a Clinical Professor of Surgery at Stanford University School of Medicine and brings decades of clinical and executive leadership experience, including her prior role at Intuitive Surgical. She currently serves on the boards of Inspire Medical Systems and Stereotaxis, and previously served as a director of Nektar Therapeutics. Mobia Medical is a commercial-stage medical device company focused on stroke recovery, with its Vivistim Paired VNS System being the first FDA-approved implantable solution for improving upper limb function in chronic ischemic stroke survivors.